When you think of arthritis, achy, warm, swollen joints probably come to mind. These are indeed some of the most common symptoms of arthritis. But did you know there are actually over 100 different ...

Swedish Orphan Biovitrum (Sobi) has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics, a move that will expand Sobi’s presence in the gout treatment ...

Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, ...

NEW YORK CITY — Urate, the culprit of gout, affects the vasculature in multiple ways that can raise cardiovascular risk (CV) in an individual with gout, and following guidelines for gout treatment, ...

The study revealed how a second drug taken orally more than doubled the effectiveness of Pegloticase, an intravenous gout treatment used to dissolve crystalized uric acid in the joints when oral ...

WASHINGTON — Different stages of gout treatment may call for different serum urate targets, with certain levels being better for dissolving or preventing monosodium urate crystals, according to data ...

“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset. Pozdeutinurad has ...

PHILADELPHIA — Patients with gout who underwent an intensive treat-to-target regimen of monthly up-titration of urate-lowering therapy (ULT) to reach a target serum urate level were significantly more ...

Per the terms of the agreement, Sobi is expected to pay upwards of $950 million upfront in cash to acquire Arthrosi.The deal ...

Please provide your email address to receive an email when new articles are posted on . Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy ...

Sobi agrees to buy Arthrosi Therapeutics for up to $1.5 billion, adding the Phase 3 gout asset pozdeutinurad to expand its ...